<DOC>
	<DOCNO>NCT00276172</DOCNO>
	<brief_summary>The primary objective study determine safety immunogenicity extend treatment natalizumab administer dose 300 mg intravenously ( IV ) subject multiple sclerosis ( MS ) complete natalizumab Studies C-1801 , C-1802 , C-1803 .</brief_summary>
	<brief_title>Open-Label Natalizumab Safety Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Must give write informed consent . Must MS subject complete natalizumab Study C1801 , C1802 C1803 History , available abnormal laboratory result , indicative significant disease would preclude treatment . History severe allergic anaphylactic reaction know drug hypersensitivity A clinically significant infectious illness within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>